Results 131 to 140 of about 2,728,807 (361)
Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia [PDF]
, 2021 Yi Fan +7 more
openalex +1 more source
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Meikuang AnquanIn order to explore the hydrogeochemical characteristics of coal seam water produced in Fukang Mining Area, the recharge relationship between stagnant aquifer and coal seam water in the fire area and the water chemical evolution model, this study ...
Donglei JIA +5 more
doaj +1 more source
An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study [PDF]
, 2019 Xiuping Zhang +14 more
openalex +1 more source
Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas [PDF]
, 2021 Franziska Lea Schümann +18 more
openalex +1 more source
Effect of chemotherapy on passenger mutations in metastatic colorectal cancer
Molecular Oncology, EarlyView.Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui +6 more
wiley +1 more source
Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]
, 2011 The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van +3 more
core +1 more source
Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer [PDF]
, 2019 Paul Buderath +6 more
openalex +1 more source